Physician profile
John M Smith
NPI 1578753869
$9,190.62
in general payments reported to CMS, 2019-2025
37 companies · $979 in 2025
The $979 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,635 · 2020: $1,413 · 2021: $1,982 · 2022: $1,669 · 2023: $1,194 · 2024: $320 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,492.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,061.32 | 2019-2025 | |
| Pfizer INC. | $1,046.10 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $882.66 | 2019-2024 | Xarelto |
| Abiomed | $686.61 | 2021-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $617.46 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $503.61 | 2019-2025 | Repatha |
| Sanofi-Aventis U.S. LLC | $499.30 | 2019-2023 | |
| Biotronik INC. | $450.75 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $377.11 | 2020-2024 | Farxiga |
| Amarin Pharma, INC. | $356.36 | 2019-2022 | |
| Abbott Laboratories | $353.01 | 2019-2024 | Jot Dx, Aveir |
| Regeneron Healthcare Solutions, INC. | $341.75 | 2019-2024 | Evkeeza, Praluent |
| Kestra Medical Technology Services, INC. | $339.86 | 2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.20 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $154.11 | 2019-2024 | Lifevest |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $141.54 | 2020-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $140.77 | 2021-2023 | |
| Stryker Corporation | $129.00 | 2025 | Flowtriever |
| Esperion Therapeutics, INC. | $126.39 | 2020-2023 | Nexletol |
| Merck Sharp & Dohme LLC | $114.62 | 2022-2024 | Verquvo |
| Medtronic, INC. | $91.73 | 2023-2025 | Linq II, In.Pact Admiral |
| Akcea Therapeutics, INC. | $76.68 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $69.12 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $54.96 | 2023 | Inpefa |
| Cvrx, INC. | $51.36 | 2023 | Barostim Neo System |
| Kowa Pharmaceuticals America, INC. | $49.12 | 2019-2022 | |
| Novo Nordisk INC | $42.05 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Boston Scientific Corporation | $40.65 | 2022-2025 | Rotablator Rotational Atherectomy System Console Kit, General - Atherectomy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.42 | 2025 | Caplyta |
| United Therapeutics Corporation | $29.96 | 2019 | |
| Alnylam Pharmaceuticals INC. | $29.10 | 2020-2021 | |
| Medtronic Vascular, INC. | $27.55 | 2019-2020 | |
| Lundbeck LLC | $20.16 | 2019 | |
| Irhythm Technologies, INC. | $16.48 | 2022 | |
| Scpharmaceuticals INC. | $12.93 | 2023 | |
| Astellas Pharma US INC | $12.48 | 2020 | |
| Itamar Medical INC | $7.34 | 2023 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.